After The Fracture
After The Fracture

Dr. Jonathan D. Adachi Recieves IOF Olof Johnell Science Award for Osteoporosis Research Contributions


Professor Jonathan D. Adachi M.D. has been named the winner of the International Osteoporosis Foundation’s (IOF) 2014 Olof Johnell Science Award. Dr. Adachi is Professor and Alliance for Better Bone Health Chair in Rheumatology at the Department of Medicine of McMaster University.

The Olof Johnell Award is granted in recognition of extraordinary and internationally recognized contributions to the field of osteoporosis in a scientific or policy implementation area. The 2014 Award was presented at a ceremony held at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Seville, Spain.

Announcing Dr. Bill Leslie as President Elect of the International Society for Clinical Densitometry

Dr. Bill Leslie

Osteoporosis Canada is proud to announce that at the recent joint IOF-ISCD (International Osteoporosis Foundation/International Society for Clinical Densitometry) conference in Orlando, Dr. Leslie was announced as the new President Elect for ISCD and was re-elected as Chair of the ISCD Canadian Panel. He is past chair of Osteoporosis Canada’s Scientific Advisory Council and has volunteered his time and clinical expertise with Osteoporosis Canada since 1997.

The International Society for Clinical Densitometry (ISCD) is a multidisciplinary, nonprofit organization dedicated to advancing excellence in the assessment of skeletal health (

Strontium Ranelate (Protelos) and Osteoporosis

Strontium ranelate (Protelos) is a drug approved for the treatment of osteoporosis in Europe, but not in Canada. It is effective in reducing fractures . Recently the European Medicines Agency has completed their review regarding the safety of this drug and recommend that strontium ranelate not be taken by patients with heart or circulatory problems. Individuals who have had a heart attack, angina, stroke or uncontrolled blood pressure should not take this medicine and should discuss their osteoporosis therapy with their physician.

The safety of strontium citrate commonly available at health food stores in Canada has not been evaluated and its effects on fracture risk reduction are not known.

Osteoporosis Canada recommends that all patients with osteoporosis or at an increased risk of fracture discuss their treatment options with their physician.

Fracture Liaison Services: Closing The Post-Fracture Care Gap


The total cost of osteoporosis in Canada was $2.3 billion in 2010. This is not surprising given that the 30,000 Canadians who experience a hip fracture each year spend an average of 23 days in hospital and rehabilitation centres at an average acute care cost of $20,000 per patient. Nearly a quarter of these end up in long-term care facilities leading to $600 million in annual costs with additional costs attributable to the 170,000 other fragility fractures per year of the spine, wrist, shoulder, pelvis and other bones. Fracture Liaison Services are proven to close the care gap and reduce costs.